Physician
Matthew F Mccarty MD PLLC
Matthew F Mccarty MD PLLC was paid $242K by Medicaid between Jan 2018 and Oct 2024, across 20 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 35% of everything it billed.
33Billing provider infoMATTHEW F MCCARTY MD PLLC
AUSTIN, TX 78749
AUSTIN, TX 78749
33aNPI1093989048assigned 04/21/2008
33bProvider typeAnesthesiology Physician
28Total paid$242K
24GClaims15,496
24DCodes billed20
24AFirst – last monthJan 2018 – Oct 2024
Compared with peers
Next to other Anesthesiology Physician providers in Texas
Rank by total paid#38 of 134
Median peer was paid$34K
This provider vs. median7.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 2,124 | $4K | |
| 2019 | 1,815 | $3K | |
| 2020 | 2,233 | $32K | |
| 2021 | 6,291 | $122K | |
| 2022 | 1,848 | $54K | |
| 2023 | 864 | $21K | |
| 2024incomplete | 321 | $7K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 35% | 3,640 | 3,419 | $85K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 28% | 3,107 | 2,950 | $68K |
| 80323 | 5.1% | 714 | 679 | $12K | |
| 80361 | 5.1% | 836 | 803 | $12K | |
| 80346 | 4.4% | 765 | 731 | $11K | |
| 80324 | 3.5% | 701 | 654 | $8K | |
| 80356 | 3.4% | 627 | 599 | $8K | |
| 80353 | 2.8% | 684 | 653 | $7K | |
| 80349 | 2.4% | 547 | 508 | $6K | |
| 80359 | 1.8% | 526 | 504 | $4K | |
| 83992 | 1.7% | 303 | 287 | $4K | |
| 80333 | 1.5% | 279 | 267 | $4K |
8 more codes
| 01992 | 1.3% | 58 | $3K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 1.3% | 671 | $3K |
| 80355 | 1.2% | 354 | $3K | |
| 80369 | <1% | 138 | $2K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 57 | $667.52 |
| 80336 | <1% | 39 | $647.90 | |
| G8730 | Pain assessment documented as positive using a standardized tool and a follow-up plan is documented | 0% | 1,300 | $0.00 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 0% | 150 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSCHOCKET, SANDFORD (CEO)
| Provider | Location | Paid |
|---|---|---|
| Nura PLLC | Minneapolis, MN | $13.79M |
| Nura PLLC | Coon Rapids, MN | $6.24M |
| Capitol Pain Institute, PA | Austin, TX | $2.48M |
| Nura Surgical Center LLC | Edina, MN | $582K |
| Pain and Aging Management LLC | Columbus, IN | $139K |
| Springs Rehabilitation Founder Holdings, PC | Colorado Springs, CO | $120K |
| Center for Specialty Surgery of Austin, LLC | Austin, TX | $0.00 |
| Water Leaf Surgery Center, LTD | Austin, TX | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.